Roivant Sciences director Oren Ilan forfeited 2,378 shares at $40.94 per share on September 10. The transaction represented about 2.0% of his prior holding and left him with 118,626 Roivant Sciences shares, giving investors the stated post-transaction measure of his ownership.
Key Highlights
- Oren Ilan held 118,626 Roivant Sciences shares after the transaction.
- The forfeiture represented about 2.0% of his prior shares holding.
- Roivant Sciences director Oren Ilan forfeited 2,378 shares.
- The shares were forfeited at $40.94 per share on September 10.
Roivant Sciences Ltd. (NASDAQ: ROIV) director Oren Ilan forfeited 2,378 shares at $40.94 per share on September 10. The transaction left Ilan with 118,626 shares.
$40.94 Share Forfeiture Leaves 118,626 Shares
Ilan was identified as a director of Roivant Sciences Ltd. The transaction involved 2,378 shares valued at $40.94 per share. The forfeiture represented about 2.0% of Ilan’s prior shares holding. The reported post-transaction balance was 118,626 shares.
FAQs
Q: What happened to Oren Ilan’s Roivant Sciences shares?
A: Director Oren Ilan forfeited 2,378 Roivant Sciences shares at $40.94 per share on September 10. The transaction left him with 118,626 shares.
Q: What does the Roivant director share transaction mean for ROIV investors?
A: For ROIV investors, the reported transaction involved Oren Ilan, a director, forfeiting 2,378 shares at $40.94 per share. The forfeiture represented about 2.0% of his prior holding and left him with 118,626 shares.
Q: Was Oren Ilan’s Roivant share transaction a sale?
A: No. The reported event was a forfeiture, not described as a sale, involving 2,378 shares at $40.94 per share. After the transaction, Ilan held 118,626 shares.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.